Insider · CIK 0001861550
Daniel S. Lorrain
officer
Files at CTNM (Contineum Therapeutics, Inc.). First filing Nov 20, 2024, latest Jul 10, 2026.
In brief
Daniel S. Lorrain files SEC Form 4 as officer at CTNM (Contineum Therapeutics, Inc.). Since Nov 20, 2024, Daniel S. Lorrain has reported 0 open-market buys worth $0 and 14 open-market sells worth $1.3M, the latest filed on Jul 10, 2026.
A track record needs three past buys with six months of prices behind them; Daniel S. Lorrain has 0, so none is measured yet.
The newest scored trade: sold $17k of CTNM on Jul 8, 2026, filed Jul 10, 2026, scored 0 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 12 sells worth $1.1M.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 14
$0 bought, $1.3M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CTNM: Contineum Therapeutics, Inc.
CTNMOct 12, 2026 · close 8.56
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Contineum Therapeutics, Inc. | $17k 1,040 shares | -1% | +320% from low-5% from high | |
| 19Weak | Contineum Therapeutics, Inc. | $595k 37,179 shares | -22% | +339% from low0% from high | |
| 2Weak | Contineum Therapeutics, Inc. | $55k 4,170 shares | -3% | +259% from low-18% from high | |
| 2Weak | Contineum Therapeutics, Inc. | $55k 4,170 shares | -3% | +288% from low-18% from high | |
| 2Weak | Contineum Therapeutics, Inc. | $56k 4,170 shares | -3% | +295% from low-16% from high | |
| 18Weak | Contineum Therapeutics, Inc. | $63k 4,170 shares | -3% | +351% from low-4% from high | |
| 6Weak | Contineum Therapeutics, Inc. | $130k 8,124 shares | -5% | +369% from low-0% from high | |
| 0Weak | Contineum Therapeutics, Inc. | $1,600 100 shares | -0% | +371% from low0% from high | |
| 0Weak | Contineum Therapeutics, Inc. | $6,400 400 shares | -0% | +349% from low-3% from high | |
| 17Weak | Contineum Therapeutics, Inc. | $62k 4,170 shares | -3% | +347% from low0% from high | |
| 9Weak | Contineum Therapeutics, Inc. | $44k 4,170 shares | -3% | +194% from low-30% from high | |
| 10Weak | Contineum Therapeutics, Inc. | $51k 4,170 shares | -2% | +262% from low-16% from high | |
| 0Weak | Contineum Therapeutics, Inc. | $16k 1,010 shares | -1% | - | |
| 5Weak | Contineum Therapeutics, Inc. | $101k 6,190 shares | -4% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 1, 2026 | CTNM Contineum Therapeutics, Inc. | 4,170 0.01% of outstanding | $56k | Oct 1, 2026 | $325k |
| Sep 1, 2026 | CTNM Contineum Therapeutics, Inc. | 9,520 0.03% of outstanding | $155k | Sep 1, 2026 | $765k |
| Aug 3, 2026 | CTNM CONTINEUM THERAPEUTIC INC | 9,520 0.03% of outstanding | $147k | Aug 3, 2026 | $668k |
| Jul 1, 2026 | CTNM Contineum Therapeutics, Inc. | 9,520 0.03% of outstanding | $156k | Jul 1, 2026 | $628k |
| Jun 30, 2026 | CTNM Contineum Therapeutics, Inc. | 28,826 0.09% of outstanding | $432k | Jun 30, 2026 | $166k |
| Jun 1, 2026 | CTNM Contineum Therapeutics, Inc. | 4,170 0.01% of outstanding | $56k | Jun 1, 2026 | $173k |
| May 1, 2026 | CTNM Contineum Therapeutics, Inc. | 4,170 0.01% of outstanding | $53k | May 1, 2026 | $319k |
| Apr 6, 2026 | CTNM CONTINEUM THERAPEUTIC INC | 914 0.00% of outstanding | $12k | Apr 6, 2026 | $263k |
| Feb 11, 2026 | CTNM Contineum Therapeutics, Inc. | 16,050 0.07% of outstanding | $253k | Feb 11, 2026 | $157k |
| Feb 3, 2026 | CTNM CONTINEUM THERAPEUTIC, INC. | 4,170 0.02% of outstanding | $60k | Feb 3, 2026 | $95k |
| Jan 5, 2026 | CTNM Contineum Therapeutics, Inc. | 4,170 0.02% of outstanding | $47k | Jan 5, 2026 | $51k |
| Dec 23, 2025 | CTNM Contineum Therapeutics, Inc. | 4,170 0.02% of outstanding | $51k | Dec 23, 2025 | none |
| Nov 18, 2024 | CTNM CONTINEUM THERAPEUTIC INC | 26,370 0.14% of outstanding | $454k | Nov 18, 2024 | none |
Transactions
Every row this insider has filed, 44 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 8, 2026 | CTNM Contineum Therapeutics, Inc. | MOption exercise Class A Common Stock10b5-1 | +1,015 | $1.01 | $1,025 | 136,217 | Jul 10, 2026 |
| Jul 8, 2026 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -1,015 | $16.00 | $16k | 135,202 | Jul 10, 2026 |
| Jul 9, 2026 | CTNM Contineum Therapeutics, Inc. | MOption exercise Class A Common Stock10b5-1 | +25 | $1.01 | $25 | 135,227 | Jul 10, 2026 |
| Jul 9, 2026 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -25 | $16.00 | $400 | 135,202 | Jul 10, 2026 |
| Jul 8, 2026 | CTNM Contineum Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -1,015 | $0.00 | $0 | 33,282 | Jul 10, 2026 |
| Jul 9, 2026 | CTNM Contineum Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -25 | $0.00 | $0 | 33,257 | Jul 10, 2026 |
| Jun 30, 2026 | CTNM Contineum Therapeutics, Inc. | MOption exercise Class A Common Stock10b5-1 | +28,826 | $1.01 | $29k | 168,198 | Jul 2, 2026 |
| Jun 30, 2026 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -28,826 | $16.04 | $462k | 139,372 | Jul 2, 2026 |
| Jul 1, 2026 | CTNM Contineum Therapeutics, Inc. | MOption exercise Class A Common Stock10b5-1 | +4,183 | $1.01 | $4,225 | 143,555 | Jul 2, 2026 |
| Jul 1, 2026 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -5,852 | $15.67 | $92k | 137,703 | Jul 2, 2026 |
| Jul 1, 2026 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -2,501 | $16.24 | $41k | 135,202 | Jul 2, 2026 |
| Jun 30, 2026 | CTNM Contineum Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -28,826 | $0.00 | $0 | 38,480 | Jul 2, 2026 |
| Jul 1, 2026 | CTNM Contineum Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -4,183 | $0.00 | $0 | 34,297 | Jul 2, 2026 |
| Jun 1, 2026 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -4,170 | $13.16 | $55k | 139,372 | Jun 1, 2026 |
| May 1, 2026 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -3,870 | $13.06 | $51k | 143,842 | May 1, 2026 |
| May 1, 2026 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -300 | $13.84 | $4,152 | 143,542 | May 1, 2026 |
| Apr 6, 2026 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -4,170 | $13.43 | $56k | 147,712 | Apr 6, 2026 |
| Mar 2, 2026 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -4,170 | $15.01 | $63k | 151,882 | Mar 2, 2026 |
| Feb 24, 2026 | CTNM Contineum Therapeutics, Inc. | MOption exercise Class A Common Stock10b5-1 | +4,300 | $1.01 | $4,343 | 160,352 | Feb 26, 2026 |
| Feb 24, 2026 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -4,300 | $16.03 | $69k | 156,052 | Feb 26, 2026 |
| Feb 25, 2026 | CTNM Contineum Therapeutics, Inc. | MOption exercise Class A Common Stock10b5-1 | +3,824 | $1.01 | $3,862 | 159,876 | Feb 26, 2026 |
| Feb 25, 2026 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -3,824 | $16.01 | $61k | 156,052 | Feb 26, 2026 |
| Feb 24, 2026 | CTNM Contineum Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -4,300 | $0.00 | $0 | 71,130 | Feb 26, 2026 |
| Feb 25, 2026 | CTNM Contineum Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -3,824 | $0.00 | $0 | 67,306 | Feb 26, 2026 |
| Feb 19, 2026 | CTNM Contineum Therapeutics, Inc. | MOption exercise Class A Common Stock10b5-1 | +100 | $1.01 | $101 | 156,152 | Feb 20, 2026 |
| Feb 19, 2026 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -100 | $16.00 | $1,600 | 156,052 | Feb 20, 2026 |
| Feb 19, 2026 | CTNM Contineum Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -100 | $0.00 | $0 | 75,430 | Feb 20, 2026 |
| Feb 11, 2026 | CTNM Contineum Therapeutics, Inc. | MOption exercise Class A Common Stock10b5-1 | +400 | $1.01 | $404 | 156,452 | Feb 13, 2026 |
| Feb 11, 2026 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -400 | $16.00 | $6,400 | 156,052 | Feb 13, 2026 |
| Feb 11, 2026 | CTNM Contineum Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -400 | $0.00 | $0 | 75,530 | Feb 13, 2026 |
| Feb 3, 2026 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -3,000 | $14.82 | $44k | 157,222 | Feb 5, 2026 |
| Feb 3, 2026 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -1,170 | $15.25 | $18k | 156,052 | Feb 5, 2026 |
| Jan 30, 2026 | CTNM Contineum Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +160,000 | $0.00 | $0 | 160,000 | Jan 30, 2026 |
| Jan 30, 2026 | CTNM Contineum Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivativeindirect: By Spouse | +6,500 | $0.00 | $0 | 6,500 | Jan 30, 2026 |
| Jan 5, 2026 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -3,670 | $10.35 | $38k | 160,722 | Jan 6, 2026 |
| Jan 5, 2026 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -500 | $11.13 | $5,565 | 160,222 | Jan 6, 2026 |
| Dec 23, 2025 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -4,170 | $12.23 | $51k | 164,392 | Dec 30, 2025 |
| Jan 31, 2025 | CTNM Contineum Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +110,000 | $0.00 | $0 | 110,000 | Jan 31, 2025 |
| Jan 31, 2025 | CTNM Contineum Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivativeindirect: By Spouse | +3,700 | $0.00 | $0 | 3,700 | Jan 31, 2025 |
| Nov 25, 2024 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -1,010 | $16.02 | $16k | 168,562 | Nov 27, 2024 |
| Nov 18, 2024 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -6,091 | $16.37 | $100k | 169,671 | Nov 20, 2024 |
| Nov 18, 2024 | CTNM Contineum Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -99 | $17.05 | $1,688 | 169,572 | Nov 20, 2024 |
| May 24, 2024 | CTNM Contineum Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | May 29, 2024 |
| May 24, 2024 | CTNM Contineum Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivativeindirect: By Spouse | +3,700 | $0.00 | $0 | 3,700 | May 29, 2024 |
Questions about Daniel S. Lorrain
Answered from the filings on this page, as of the latest one.
Is Daniel S. Lorrain buying or selling?
In the last 12 months Daniel S. Lorrain reported 0 open-market buys worth $0 and 12 open-market sells worth $1.1M on SEC Form 4; the latest was sold $17k of CTNM on Jul 8, 2026. Grants, option exercises and tax withholding are not counted.
How did Daniel S. Lorrain's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Daniel S. Lorrain has 0.
Where does Daniel S. Lorrain file Form 4?
Daniel S. Lorrain has filed Form 4 at CTNM (Contineum Therapeutics, Inc.) as Chief Scientific Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.